XML 73 R54.htm IDEA: XBRL DOCUMENT v3.4.0.3
SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Schedule of segment revenues and profit
Segment revenues and profit for the years ended December 31, 2015, 2014 and 2013 were as follows:
 
 
2015
 
2014
(Restated)
 
2013
Revenues:
 
 
 
 
 
 
Developed Markets(1)
 
$
8,537.3

 
$
6,109.6

 
$
4,293.2

Emerging Markets(2)
 
1,909.2

 
2,096.4

 
1,476.4

Total revenues
 
10,446.5

 
8,206.0

 
5,769.6

Segment profit:
 
 
 
 
 
 
Developed Markets(3)
 
2,463.8

 
1,980.7

 
573.2

Emerging Markets(4)
 
238.5

 
337.3

 
93.0

Total segment profit
 
2,702.3

 
2,318.0

 
666.2

Corporate(5)
 
(293.0
)
 
(171.1
)
 
(165.7
)
Restructuring, integration and other costs
 
(361.9
)
 
(381.7
)
 
(462.0
)
In-process research and development impairments and other charges
 
(248.4
)
 
(41.0
)
 
(153.6
)
Acquisition-related costs
 
(38.5
)
 
(6.3
)
 
(36.4
)
Acquisition-related contingent consideration
 
23.0

 
14.1

 
29.2

Other (expense) income
 
(256.1
)
 
268.7

 
(287.2
)
Operating income (loss)
 
1,527.4

 
2,000.7

 
(409.5
)
Interest income
 
3.3

 
5.0

 
8.0

Interest expense
 
(1,563.2
)
 
(971.0
)
 
(844.3
)
Loss on extinguishment of debt
 
(20.0
)
 
(129.6
)
 
(65.0
)
Foreign exchange and other
 
(102.8
)
 
(144.1
)
 
(9.4
)
Gain on investments, net
 
—

 
292.6

 
5.8

(Loss) Income before provision for (recovery of) income taxes
 
$
(155.3
)
 
$
1,053.6

 
$
(1,314.4
)
____________________________________
(1)
Developed Markets segment revenues reflect (i) incremental product sales revenue in 2015 from 2014 and 2015 acquisitions of $2.12 billion, in the aggregate, primarily from the Salix Acquisition and the acquisitions of certain assets of both Marathon and Dendreon and (ii) incremental product sales revenue in 2014 from 2013 and 2014 acquisitions of $1.70 billion, in the aggregate, primarily from the 2013 acquisition of B&L and the 2014 acquisition of Solta Medical and PreCision.
(2)
Emerging Markets segment revenues reflect (i) incremental product sales revenue in 2015 from 2014 and 2015 acquisitions of $92 million, in the aggregate, primarily from 2014 and 2015 acquisitions and (ii) incremental product sales revenue in 2014 from 2013 and 2014 acquisitions of $581 million, in the aggregate, primarily from the 2013 acquisition of B&L and the 2014 acquisition of Solta Medical.
(3)
Developed Markets segment profit in 2015, 2014 and 2013 reflects the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets as follows: (i) $2.22 billion in 2015, in the aggregate, primarily from the Salix Acquisition, (ii) $906 million in 2014, in the aggregate, and (iii) $1.08 billion in 2013, in the aggregate.
Developed Markets segment profit in 2013 also reflects an impairment charge of $552 million related to ezogabine/retigabine in the third quarter of 2013 (see Note 7 for further information).
(4)
Emerging Markets segment profit in 2015, 2014 and 2013 reflects the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets as follows: (i) $323 million in 2015, in the aggregate, (ii) $324 million in 2014, in the aggregate, and (iii) $321 million in 2013, in the aggregate.
(5)
Corporate reflects non-restructuring-related share-based compensation expense of $95 million, $40 million and $46 million in 2015, 2014 and 2013, respectively.
Schedule of total assets by segment
Total assets by segment as of December 31, 2015, 2014 and 2013 were as follows:
 
 
2015
 
2014(1)
(Restated)
 
2013(1)
Assets:
 
 
 
 
 
 
Developed Markets(2)
 
$
41,182.7

 
$
19,070.8

 
$
20,007.2

Emerging Markets(2)
 
6,897.4

 
6,332.9

 
6,907.8

 
 
48,080.1

 
25,403.7

 
26,915.0

Corporate
 
884.4

 
901.0

 
1,017.9

Total assets
 
$
48,964.5

 
$
26,304.7

 
$
27,932.9

____________________________________
(1)
As described in Note 3, the Company adopted guidance issued by the FASB retrospectively (impacted presentation only) resulting in reclassifications between assets and long-term debt which did not have a material impact on the Company's financial statements.
(2)
Segment assets as of December 31, 2015 were impacted by the identifiable intangible assets and goodwill from the various acquisitions in the current year. See Note 4 for additional information regarding the current year acquisitions.
Schedule of capital expenditures, depreciation and amortization by segment
Capital expenditures, and depreciation and amortization, including impairments of finite-lived intangible assets by segment for the years ended December 31, 2015, 2014 and 2013 were as follows:
 
 
2015

2014

2013
Capital expenditures:
 
 
 
 
 
 
Developed Markets
 
$
190.7

 
$
152.7

 
$
54.1

Emerging Markets
 
26.9

 
29.3

 
51.9

 
 
217.6

 
182.0

 
106.0

Corporate
 
17.6

 
109.6

 
9.3

Total capital expenditures
 
$
235.2

 
$
291.6

 
$
115.3

Depreciation and amortization, including impairments of finite-lived intangible assets(1):
 
 
 
 
 
 
Developed Markets
 
$
2,245.9

 
$
1,336.9

 
$
1,687.7

Emerging Markets
 
354.7

 
385.7

 
313.7

 
 
2,600.6

 
1,722.6

 
2,001.4

Corporate
 
26.9

 
15.0

 
14.4

Total depreciation and amortization, including impairments of finite-lived intangible assets
 
$
2,627.5

 
$
1,737.6

 
$
2,015.8

____________________________________
(1)
Depreciation and amortization, including impairments of finite-lived intangible assets in 2015, 2014 and 2013 reflects the impact of acquisition accounting adjustments related to the fair value adjustments to identifiable intangible assets.
For more information regarding business combinations and asset impairment charges and write-offs, see Note 4, Note 7 and Note 11.
Schedule of revenues by product category
Revenues by product category for the years ended December 31, 2015, 2014 and 2013 were as follows:
 
 
2015
 
2014
(Restated)
 
2013
Pharmaceuticals
 
$
6,094.3

 
$
3,445.3

 
$
2,677.6

Devices
 
1,494.6

 
1,629.4

 
845.3

OTC
 
1,582.9

 
1,711.4

 
1,086.6

Branded and Other Generics
 
1,120.4

 
1,260.0

 
1,030.8

Other revenues
 
154.3

 
159.9

 
129.3

 
 
$
10,446.5

 
$
8,206.0

 
$
5,769.6
Schedule of revenues and long-lived assets by geographic region
Revenues by geographic region for the years ended December 31, 2015, 2014 and 2013 were as follows:
 
 
Revenues(1)
 
 
2015
 
2014
(Restated)
 
2013
U.S. and Puerto Rico
 
$
7,063.0

 
$
4,415.5

 
$
3,194.5

Canada
 
333.6

 
375.1

 
387.4

China
 
271.5

 
232.0

 
91.0

Poland
 
213.5

 
276.2

 
268.8

Japan
 
206.4

 
248.7

 
104.9

Mexico
 
203.9

 
221.6

 
200.9

Australia
 
182.3

 
196.3

 
178.2

France
 
178.3

 
204.7

 
86.9

Russia
 
168.9

 
275.1

 
202.8

Germany
 
159.4

 
204.4

 
130.9

Brazil
 
110.2

 
161.0

 
155.6

U.K.
 
105.1

 
114.2

 
47.0

Other (2)
 
1,250.4

 
1,281.2

 
720.7

 
 
$
10,446.5

 
$
8,206.0

 
$
5,769.6

____________________________________
(1)
Revenues are attributed to countries based on the location of the customer.
(2)
Other consists primarily of countries in Europe, Asia, Africa, the Middle East, and Latin America.
Schedule of assets by geographic region
Long-lived assets by geographic region as of December 31, 2015, 2014 and 2013 were as follows:
 
 
Long-Lived Assets(1)
 
 
2015
 
2014
(Restated)
 
2013
U.S. and Puerto Rico
 
$
824.3

 
$
720.0

 
$
592.0

Egypt(2)
 
97.3

 
—

 
—

Poland
 
88.6

 
99.4

 
110.0

Canada
 
75.6

 
83.7

 
87.7

Germany
 
62.6

 
73.5

 
83.8

Mexico
 
62.3

 
73.8

 
82.5

China
 
32.7

 
39.6

 
44.3

France
 
29.9

 
36.0

 
40.5

Serbia
 
27.3

 
31.8

 
40.0

Italy
 
20.7

 
23.1

 
25.3

Brazil
 
20.4

 
31.4

 
41.4

Other (3)
 
100.1

 
100.0

 
86.7

 
 
$
1,441.8

 
$
1,312.3

 
$
1,234.2

____________________________________
(1)
Long-lived assets consist of property, plant and equipment, net of accumulated depreciation, which is attributed to countries based on the physical location of the assets.
(2)
Relates to the Amoun Acquisition, described further in Note 4.
(3)
Other consists primarily of countries in Europe, Asia, Latin America, and the Middle East.
Schedule of external customers that accounted for 10% or more of total revenues
External customers that accounted for 10% or more of the Company’s total revenues for the years ended December 31, 2015, 2014 and 2013 were as follows:


2015

2014

2013
McKesson Corporation

20%

17%

19%
AmerisourceBergen Corporation

14%

10%

7%
Cardinal Health, Inc.

12%

9%

13%